Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

Documenti analoghi

• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study
  di: Naimi, Rahim Mohammad, et al.
  Pubblicazione: (2021)
• Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome
  di: Jeppesen, Palle Bekker
  Pubblicazione: (2012)
• Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
  di: Michel, Martin C., et al.
  Pubblicazione: (2008)
• Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV
  di: Bjelke, Jais R., et al.
  Pubblicazione: (2006)
• Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
  di: Shaker A Mousa, et al.
  Pubblicazione: (2019-01-01)